Loading...

News List

Vijoice是美国FDA批准的首个PROS治疗药物

2022-07-06


Vijoice是美国FDA批准的首个PROS治疗药物

2022.04.06,诺华(Novartis)宣布,美国FDA加速批准Vijoice(alpelisib)用于需要接受系统治疗的、患有严重表现的PIK3CA相关过度生长谱系(PROS)成人和2岁及以上儿童患者. Vijoice是美国FDA批准的首个PROS治疗药物. PROS泛指因PIK3CA基因突变所致病谱系,特征为血管、淋巴系统和其他组织非典型过度生长和异常. (注:2019.05.24, 美国FDA批准alpelisib用于治疗乳腺癌)

Pre: Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib

Next: Vijoice is the first FDA-approved PRS treatment

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.